Monthly Archives: October 2024

Tirzepatide is a dual receptor agonist that activates both GLP-1 and GIP receptors. It has received FDA approval for the treatment of type 2 diabetes and it is under regulatory review for obesity treatment [14]. Although there are no head-to-head clinical trials comparing tirzepatide and retatrutide, early research indicates that retatrutide might lead to greater […]

Retatrutide vs Semaglutide are both peptide-based therapies that target metabolic pathways for weight loss and glucose control. Semaglutide acts as a GLP-1 receptor agonist, enhancing insulin secretion and reducing appetite. Retatrutide, on the other hand, is a triple receptor agonist that stimulates GLP-1, GIP, and GCG receptors, potentially offering more significant weight loss and improved […]

Retatrutide is supplied as a lyophilized powder intended for research purposes and must be reconstituted with either bacteriostatic water or sterile water. Bacteriostatic water, which contains 0.9% benzyl alcohol, is preferred for reconstitution because it inhibits bacterial growth, allowing the peptide to remain stable for up to four weeks when refrigerated properly at 36 to […]

Retatrutide has not yet been approved for any form of human use; however, it is available to qualified researchers for studying its therapeutic potential as a triple receptor agonist. Retatrutide is currently undergoing clinical development within Eli Lilly’s TRIUMPH phase-3 clinical program, which aims to gather extensive data on its efficacy and safety. This program […]